Literature DB >> 9182651

New and classical risk factors--the Münster heart study (PROCAM).

G Assmann1, H Schulte, P Cullen.   

Abstract

A total of 4,849 male participants of the prospective cardiovascular Münster Study (PROCAM), aged 40 - 65 years underwent extensive screening for cardiovascular risk factors before 1986 and were subsequently followed up for at least 8 years. During this time 189 non-fatal and 49 fatal myocardial infarctions occurred, 28 men suffered a sudden cardiac death and 169 persons died of other causes. Using multivariate statistical methods we confirmed that age, increased LDL cholesterol levels, decreased HDL cholesterol levels, high blood pressure, cigarette smoking, diabetes mellitus, angina pectoris and a positive family history are important risk factors for a myocardial infarction or cardiac death. The results of the PROCAM Study demonstrate that elevated triglycerides are an independent risk factor for an early myocardial infarction or cardiac death. Using a multiple logistic function analysis an algorithm for the assessment of the global risk was derived from the data. The observed incidence of coronary heart disease rises sharply as the global risk increases, thus permitting the use of this algorithm in clinical practice for the assessment of the individual risk of myocardial infarction. Risk factors such as lipoprotein(a) and coagulation factors may improve the predictive value of this algorithm. Furthermore it is expected that the exploration of genetic defects will strongly increase the predictive value and precise determination of individual risk.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9182651

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  23 in total

Review 1.  Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.

Authors:  David H Fitchett; Lawrence A Leiter; Shaun G Goodman; Anatoly Langer
Journal:  Can J Cardiol       Date:  2006-08       Impact factor: 5.223

2.  [Prevalence of arterial hypertension in the population of Western Germany: Heinz Nixdorf Recall Study].

Authors:  M Horacek; S Möhlenkamp; A A Mahabadi; S Churzidse; S Moebus; K-H Jöckel; R Erbel
Journal:  Herz       Date:  2012-11       Impact factor: 1.443

3.  [Genetic analyses as basis for a personalized medicine in patients with coronary artery disease].

Authors:  T Kessler; B Kaess; F Bourier; J Erdmann; H Schunkert
Journal:  Herz       Date:  2014-03       Impact factor: 1.443

Review 4.  Hypertriglyceridemia-why, when and how should it be treated?

Authors:  I Gouni-Berthold; W Krone
Journal:  Z Kardiol       Date:  2005-11

Review 5.  [Genetic testing in polygenic diseases : Atrial fibrillation, arterial hypertension and coronary artery disease].

Authors:  T Trenkwalder; T Kessler; H Schunkert
Journal:  Herz       Date:  2017-08       Impact factor: 1.443

6.  Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: impact of dietary n-3 fatty acids.

Authors:  E Levy; S Spahis; E Ziv; A Marette; M Elchebly; M Lambert; E Delvin
Journal:  Diabetologia       Date:  2006-06-21       Impact factor: 10.122

7.  Fish oil -- how does it reduce plasma triglycerides?

Authors:  Gregory C Shearer; Olga V Savinova; William S Harris
Journal:  Biochim Biophys Acta       Date:  2011-10-25

8.  Cardiovascular risk factors and signs of subclinical atherosclerosis in the Heinz Nixdorf Recall Study.

Authors:  Raimund Erbel; Stefan Möhlenkamp; Karl-Heinz Jöckel; Nils Lehmann; Susanne Moebus; Barbara Hoffmann; Axel Schmermund; Andreas Stang; Johannes Siegrist; Nico Dragano; Dietrich Grönemeyer; Rainer Seibel; Klaus Mann; Martina Bröcker-Preuss; Knut Kröger; Lothar Volbracht
Journal:  Dtsch Arztebl Int       Date:  2008-01-07       Impact factor: 5.594

9.  Atorvastatin versus Bezafibrate in Mixed Hyperlipidaemia : Randomised Clinical Trial of Efficacy and Safety (the ATOMIX Study).

Authors:  Emilio Ros; Josefina Oliván; José M Mostaza; Miquel Vilardell; Xavier Pintó; Fernando Civeira; A Hernández; Pedro Marqués da Silva; A Rodriguez-Botaro; Daniel Zambón; Joan Lima; José A Gómez-Gerique; Cristina Díaz; Rosa Arístegui; José M Sol; Gonzalo Hernández
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 10.  Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.

Authors:  Kurt Neeser; Georg Lübben; Uwe Siebert; Wendelin Schramm
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.